ファブラザイムの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイト＆予測

ファブラザイムの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13%で20億7,960万米ドルまで拡大します。予測期間の成長は、ファブリー病に対する認識の高まり、遺伝子検査の進歩、患者数の増加、規制支援と償還施策、希少疾患への注目などに起因すると考えられます。予測期間における主要動向としては、診断率の上昇、技術の進歩、新興市場の拡大、持続可能性への取り組み、デジタル変革などが挙げられます。

遺伝性疾患の有病率の増加は、ファブラザイム市場の成長を促進すると予想されます。遺伝子疾患は、個人の遺伝物質の異常によって引き起こされる健康状態です。遺伝性疾患の増加は、先進的な診断技術により多くの症例が検出されるようになったことに加え、親になる時期が遅れたり、環境の影響やライフスタイルの変化が遺伝子の変異に寄与するなどの要因によるところが大きいです。酵素補充療法であるファブラザイムは、α-ガラクトシダーゼAという酵素の欠乏によって引き起こされる遺伝性疾患であるファブリー病の治療に使用されます。例えば、2024年3月、英国を拠点とする慈善団体ジーン・ピープルは、英国では6,000以上の遺伝子疾患が診断され、約25人に1人の幼児が影響を受けていると報告しました。その結果、年間約3万人が新たに診断され、現在240万人以上が遺伝的疾患を抱えて生活しています。そのため、遺伝性疾患の増加がファブラザイム市場を促進しています。

ヘルスケア支出の増加は、ファブラザイム市場の成長をさらに促進すると予想されます。ヘルスケア支出とは、医療サービスや関連活動に費やされる総額のことで、通常は毎年測定されます。ヘルスケア支出の増加は、高齢化、慢性疾患、サービス価格の上昇、需要の増加、技術の進歩、薬剤費の上昇などの要因によるものです。ファブラザイムは、酵素補充療法を通じてファブリー病の根本的な原因に対処するもので、より良い疾病管理を可能にし、費用のかかる緊急介入の必要性を減らし、最終的に患者の転帰を改善することから、医療費増加の恩恵を受けています。例えば、国立医療図書館の報告によると、米国のヘルスケア支出は2022年に4.1％増加し、2021年の3.2％増を上回る4兆5,000億米ドルに達しました。したがって、ヘルスケア支出の増加がファブラザイム市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のファブラザイム：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のファブラザイム市場：成長率分析
• 世界のファブラザイム市場の実績：規模と成長、2019～2024年
• 世界のファブラザイム市場の予測：規模と成長、2024～2029年、2034年
• 世界のファブラザイム：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のファブラザイム市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 5mg/バイアル
• 35mg/バイアル
• 世界のファブラザイム市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• ファブリー病
• 腎機能障害
• 心臓病変
• 神経障害性疼痛
• 脳卒中予防
• 世界のファブラザイム市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ドラッグストア
• 世界のファブラザイム市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児
• 成人

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のファブラザイム市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のファブラザイム市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ファブラザイム市場：競合情勢
• ファブラザイム市場：企業プロファイル
  • Sanofi S.A.
  • JCR Pharmaceuticals
  • mAbxience

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ファブラザイム市場、2029年：新たな機会を提供する国
• ファブラザイム市場、2029年：新たな機会を提供するセグメント
• ファブラザイム市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Fabrazyme is a prescription medication primarily used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency results in the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues, leading to serious health complications such as kidney damage, heart issues, and neurological problems.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of fabrazyme include the 5 mg/vial and 35 mg/vial formulations. The 5 mg/vial refers to Fabrazyme supplied in single-dose vials containing 5 milligrams of the active ingredient, agalsidase beta. These formulations are used in hospitals and drug stores, with end users including both pediatric and adult patients.

The fabrazyme market research report is one of a series of new reports from The Business Research Company that provides fabrazyme market statistics, including fabrazyme industry global market size, regional shares, competitors with a fabrazyme market share, detailed fabrazyme market segments, market trends and opportunities, and any further data you may need to thrive in the fabrazyme industry. This fabrazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fabrazyme market size is expected to see rapid growth in the next few years. It will grow to $2,079.6 million in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing recognition of Fabry disease, advancements in genetic testing, rising patient population, regulatory Support and reimbursement policies, and focus on rare diseases. Major trends in the forecast period include increasing diagnosis rates, technological advancements, emerging market expansion, sustainability initiatives, and digital transformation.

The increasing prevalence of genetic disorders is expected to drive the growth of the fabrazyme market. Genetic disorders are health conditions caused by abnormalities in an individual's genetic material. The rise in genetic disorders is largely due to advanced diagnostic technologies detecting more cases, along with factors like delayed parenthood, environmental influences, and lifestyle changes contributing to genetic mutations. Fabrazyme, an enzyme replacement therapy, is used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. It helps break down certain lipids that accumulate in the body, reducing organ damage risk, alleviating symptoms, and improving overall quality of life. For instance, in March 2024, Gene People, a UK-based charity, reported that over 6,000 genetic conditions are diagnosed in the UK, affecting approximately 1 in 25 children. This results in about 30,000 new diagnoses annually, with more than 2.4 million people currently living with a genetic condition. Therefore, the rising number of genetic disorders is propelling the fabrazyme market.

Increasing healthcare expenditure is expected to further drive the growth of the fabrazyme market. Healthcare expenditure refers to the total amount spent on health services and related activities, typically measured annually. The rise in healthcare expenditure is attributed to factors such as an aging population, chronic diseases, higher service prices, increased demand, technological advancements, and rising drug costs. Fabrazyme addresses the underlying causes of Fabry disease through enzyme replacement therapy, which benefits from increased healthcare spending as it allows for better disease management, reduces the need for costly emergency interventions, and ultimately improves patient outcomes. For example, the National Library of Medicine reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, faster than the 3.2% growth seen in 2021. Therefore, rising healthcare expenditure is fueling the growth of the fabrazyme market.

The rise of personalized medicine is expected to contribute to the growth of the fabrazyme market. Personalized medicine is a treatment approach that tailors healthcare strategies to an individual's genetic makeup, environment, and lifestyle, aiming for more effective and precise outcomes. The rise in personalized medicine is driven by advancements in genomic technologies, a greater understanding of molecular biology, increased availability of precision diagnostic tools, and a demand for targeted therapies that enhance patient outcomes while minimizing side effects. Fabrazyme supports personalized medicine by providing enzyme replacement therapy tailored to the specific genetic and metabolic needs of patients with Fabry disease, improving therapeutic efficacy and clinical outcomes. For example, in 2022, the FDA approved personalized medicines for 34% of new drugs, according to the Personalized Medicine Coalition. This demonstrates the growing trend in personalized medicine, which is driving the fabrazyme market forward.

Major players operating in the fabrazyme market are Sanofi S.A., JCR Pharmaceuticals, mAbxience

North America was the largest region in the Fabrazyme market in 2024. The regions covered in fabrazyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabrazyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabrazyme market consists of sales of the enzyme replacement therapy (ERT) known as Fabrazyme (agalsidase beta), Replagal (agalsidase alpha), Oral Chaperone Therapies, Substrate Reduction Therapies (SRT). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabrazyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabrazyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabrazyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabrazyme market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 5mg/vial; 35mg/vial
• 2) By Indication: Fabry Disease; Renal Impairment; Cardiac Involvement; Neuropathic Pain; Stroke Prevention
• 2) By Application: Hospital; Drug store
• 3) By End-User: Pediatric; Adult
• Companies Mentioned: Sanofi S.A.; JCR Pharmaceuticals; mAbxience
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fabrazyme Market Characteristics

3. Fabrazyme Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Fabrazyme Market Trends And Strategies

5. Fabrazyme Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Fabrazyme Growth Analysis And Strategic Analysis Framework

• 6.1. Global Fabrazyme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Fabrazyme Market Growth Rate Analysis
• 6.4. Global Fabrazyme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Fabrazyme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Fabrazyme Total Addressable Market (TAM)

7. Global Fabrazyme Market Pricing Analysis & Forecasts

8. Fabrazyme Market Segmentation

• 8.1. Global Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5mg/vial
• 35mg/vial
• 8.2. Global Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fabry Disease
• Renal Impairment
• Cardiac Involvement
• Neuropathic Pain
• Stroke Prevention
• 8.3. Global Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Drug store
• 8.4. Global Fabrazyme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult

9. Global Fabrazyme Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Fabrazyme Market Regional And Country Analysis

• 10.1. Global Fabrazyme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Fabrazyme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Fabrazyme Market

• 11.1. Asia-Pacific Fabrazyme Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Fabrazyme Market

• 12.1. China Fabrazyme Market Overview
• 12.2. China Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Fabrazyme Market

• 13.1. India Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Fabrazyme Market

• 14.1. Japan Fabrazyme Market Overview
• 14.2. Japan Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Fabrazyme Market

• 15.1. Australia Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Fabrazyme Market

• 16.1. South Korea Fabrazyme Market Overview
• 16.2. South Korea Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Fabrazyme Market

• 17.1. Western Europe Fabrazyme Market Overview
• 17.2. Western Europe Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Fabrazyme Market

• 18.1. UK Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Fabrazyme Market

• 19.1. Germany Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Fabrazyme Market

• 20.1. France Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fabrazyme Market

• 21.1. Eastern Europe Fabrazyme Market Overview
• 21.2. Eastern Europe Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Fabrazyme Market

• 22.1. North America Fabrazyme Market Overview
• 22.2. North America Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Fabrazyme Market

• 23.1. USA Fabrazyme Market Overview
• 23.2. USA Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Fabrazyme Market

• 24.1. Canada Fabrazyme Market Overview
• 24.2. Canada Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Fabrazyme Market

• 25.1. South America Fabrazyme Market Overview
• 25.2. South America Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Fabrazyme Market

• 26.1. Middle East Fabrazyme Market Overview
• 26.2. Middle East Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Fabrazyme Market

• 27.1. Africa Fabrazyme Market Overview
• 27.2. Africa Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Fabrazyme Market Competitive Landscape And Company Profiles

• 28.1. Fabrazyme Market Competitive Landscape
• 28.2. Fabrazyme Market Company Profiles
  • 28.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. JCR Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. mAbxience Overview, Products and Services, Strategy and Financial Analysis

29. Global Fabrazyme Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Fabrazyme Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Fabrazyme Market

32. Recent Developments In The Fabrazyme Market

33. Fabrazyme Market High Potential Countries, Segments and Strategies

• 33.1 Fabrazyme Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Fabrazyme Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Fabrazyme Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer